Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 18 November 2022, 20:00 HKT/SGT
Share:
    

Source: China Medical System Holdings Ltd.
China Medical System (867.HK) S&P Global CSA Score Achieved Significant Improvement, Leading the Industry Globally

SHENZHEN, CHINA, Nov 18, 2022 - (ACN Newswire) - Recently, the S&P Global Corporate Sustainability Assessment (S&P Global CSA) released the 2022 Environmental, Social and Governance (ESG) scores for China Medical System Holdings Limited ("CMS" or the "Group"). CMS achieved a significant improvement with a score of 53 in 2022 from 36 in 2021, surpassing 92% of the global peers and being significantly ahead of the industry average. This result shows the Company's outstanding achievement from its active integration of ESG governance into strategic development and daily operation.

S&P Global CSA is the global leading assessment tool of corporate sustainability practices initiated by S&P Global. S&P Global CSA provides comprehensive evaluation on corporate sustainability performance, and the Group's identification and management abilities of potential opportunities and challenges by considering factors, such as corporate economy and governance, environment protection, and social responsibility. S&P Global CSA has been regarded, by stakeholders, as one of the most important references for making business or investment decisions.

Based on a well-established, scientific and effective ESG governance structure, CMS has been continuously improving its overall operations with the concept of sustainable development. Its latest S&P Global CSA-ESG scores indicated the Group has achieved significant improvements in several issues including Human Rights, Occupational Health & Safety, Supply Chain Management, Product Quality Management, Information Security & Cyber Security, Environment Policy & Management Systems, Addressing Cost Burden and Improving Access to Healthcare. Especially, the Group received excellent scores in Marketing Practices, Product Quality Management, and Addressing Cost Burden.

Adhering to compliant operations, CMS has built an honest, efficient, and open operational culture via a solid internal management system. By continuously enhancing its innovative product incubation platform and fully leveraging its strengths, the Group promotes diversified collaborative R&D and continues to build a pharmaceutical ecosystem in a collaborative setting for the benefit of all stakeholders, to improve pharmaceutical R&D efficiency, and constantly offer patients with accessible, affordable, and quality products. In the future, upholding visionary corporate mission and responsibility, CMS said it will continuously enhance its corporate governance, environment control practices, and social responsibility fulfillment, and promote the integration of ESG concepts into the Group's strategy, striving to be the leading sustainable pharmaceutical company in China.

Media Contact
Media Team, CMS
Email: ir@cms.net.cn
Website: http://www.cms.net.cn/

Source: China Medical System Holdings Ltd.


Topic: Press release summary
Source: China Medical System Holdings Ltd.

Sectors: Healthcare & Pharm, MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



China Medical System Holdings Ltd.
Oct 21, 2024 10:00 HKT/SGT
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area
Sept 24, 2024 21:00 HKT/SGT
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Aug 16, 2024 13:00 HKT/SGT
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 5, 2024 22:00 HKT/SGT
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
July 16, 2024 20:00 HKT/SGT
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
June 25, 2024 20:00 HKT/SGT
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
June 18, 2024 18:45 HKT/SGT
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
Apr 23, 2024 22:00 HKT/SGT
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 1, 2024 20:30 HKT/SGT
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Mar 28, 2024 10:23 HKT/SGT
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: